2024
A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity
Kalinichenko S, Ramadan L, Kruglova N, Balagurov K, Lukashina M, Mazurov D, Shepelev M. A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity. Biology 2024, 13: 675. PMID: 39336102, PMCID: PMC11428423, DOI: 10.3390/biology13090675.Peer-Reviewed Original ResearchCellular cytotoxicityHIV-1Chimeric antibodyInhibitors of HIV-1 entryAntibody-dependent cellular cytotoxicityHIV-1 infectionHIV-1 entryRecombinant chimeric antibodyHumanized antibody trastuzumabMouse monoclonal antibodyCXCR4 locusCD4 lymphocytesCD4 cellsParental mouse monoclonal antibodyCAR cellsGeneration of antibodiesAntibody trastuzumabMonoclonal antibodiesAntibodiesMouse hybridomasConstant regionKnock-inCellsCytotoxicityPeptide
2022
Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41
Maslennikova A, Kruglova N, Kalinichenko S, Komkov D, Shepelev M, Golubev D, Siniavin A, Vzorov A, Filatov A, Mazurov D. Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of gp41. MBio 2022, 13: e03589-21. PMID: 35073736, PMCID: PMC8787484, DOI: 10.1128/mbio.03589-21.Peer-Reviewed Original ResearchConceptsHIV-1 infectionCD4 lymphocytesHIV-1Antiretroviral therapyLentiviral vectorsT cellsHeptad repeat 2Resistance to HIV-1 infectionTherapy of HIV infectionInhibitors of HIV-1 entryHIV-1 proviral DNATherapeutic lentiviral vectorInhibitors of HIV-1 fusionHIV-1 entryKnock-inCell surfaceT cell linesHIV-1 fusionProtection of lymphocytesKnock-in (KIGene modificationLatent provirusesHIV infectionViral clearanceFusion inhibitory peptides
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply